120 related articles for article (PubMed ID: 29579855)
1. Renal Transplant Immunosuppression in Patients With Hemolytic Uremic Syndrome: Four Case Reports.
Galindo P; Ramirez M; Pérez Marfil A; Espigares MJ; Osoria JM; Leiva R; Ruiz Fuentes MC; De Gracia C; Osuna A
Transplant Proc; 2018 Mar; 50(2):572-574. PubMed ID: 29579855
[TBL] [Abstract][Full Text] [Related]
2. A case of atypical hemolytic uremic syndrome in a second renal transplant.
Zwang NA; Ho B; Kanwar YS; Lewis B; Cusick M; Friedewald JJ; Gallon L
J Nephrol; 2018 Feb; 31(1):165-172. PubMed ID: 28224376
[TBL] [Abstract][Full Text] [Related]
3. Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients.
Raina R; Chauvin A; Fox K; Kesav N; Ascha M; Vachharajani TJ; Krishnappa V
Ann Transplant; 2018 Sep; 23():631-638. PubMed ID: 30190449
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
Okumi M; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
[TBL] [Abstract][Full Text] [Related]
5. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
[TBL] [Abstract][Full Text] [Related]
6. Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation.
Kawaguchi K; Kawanishi K; Sato M; Itabashi M; Fujii A; Kanetsuna Y; Huchinoue S; Ohashi R; Koike J; Honda K; Nagashima Y; Nitta K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():61-5. PubMed ID: 26031589
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Plasma Exchange in Pediatric Renal Transplantation Experience of One Decade and 389 Sessions.
Runowski D; Prokurat S; Rubik J; Grenda R
Transplant Proc; 2018 Dec; 50(10):3483-3486. PubMed ID: 30577225
[TBL] [Abstract][Full Text] [Related]
8. Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome.
Hofer J; Giner T; Cortina G; Jungraithmayr T; Masalskiene J; Dobiliene D; Mitkiene R; Pundziene B; Rudaitis S
Pediatr Transplant; 2015 Aug; 19(5):E121-5. PubMed ID: 26037622
[TBL] [Abstract][Full Text] [Related]
9. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.
Salameh H; Abu Omar M; Alhariri A; Kisra S; Qasem A; Abdulhak AB
Am J Ther; 2016; 23(4):e1110-5. PubMed ID: 25486517
[TBL] [Abstract][Full Text] [Related]
10. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Noris M; Remuzzi G
Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
van den Brand JA; Verhave JC; Adang EM; Wetzels JF
Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i115-i122. PubMed ID: 28391343
[TBL] [Abstract][Full Text] [Related]
12. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
Levi C; Frémeaux-Bacchi V; Zuber J; Rabant M; Devriese M; Snanoudj R; Scemla A; Amrouche L; Mejean A; Legendre C; Sberro-Soussan R
Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
[TBL] [Abstract][Full Text] [Related]
13. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab
.
Riddell A; Goodship T; Bingham C
Clin Nephrol; 2016 Oct; 86(10):200-2. PubMed ID: 27616760
[TBL] [Abstract][Full Text] [Related]
14. [Genetics of aHUS and transplant recurrence].
Bresin E
G Ital Nefrol; 2015; 32 Suppl 64():. PubMed ID: 26479051
[TBL] [Abstract][Full Text] [Related]
15. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
Loirat C; Fakhouri F; Ariceta G; Besbas N; Bitzan M; Bjerre A; Coppo R; Emma F; Johnson S; Karpman D; Landau D; Langman CB; Lapeyraque AL; Licht C; Nester C; Pecoraro C; Riedl M; van de Kar NC; Van de Walle J; Vivarelli M; Frémeaux-Bacchi V;
Pediatr Nephrol; 2016 Jan; 31(1):15-39. PubMed ID: 25859752
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
17. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
Ranch D; Crowther B; Arar M; Assanasen C
Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
[TBL] [Abstract][Full Text] [Related]
19. Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant.
Stevenson S; Mallett A; Oliver K; Hyland V; Hawley C; Malmanche T; Isbel N
Nephrology (Carlton); 2014 Apr; 19 Suppl 1():22-6. PubMed ID: 24460647
[TBL] [Abstract][Full Text] [Related]
20. Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Grenda R; Jarmużek W; Rubik J; Prokurat S; Miklaszewska M; Drozdz D; Zachwieja K; Ardissino G; Hofer J
Pediatr Transplant; 2015 Sep; 19(6):E130-4. PubMed ID: 26087050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
